The US Patent and Trademark Office (USPTO) has granted three new patents to A.P. Pharma's new APF530 drug delivery candidate.
The company said APF530 drug candidate is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting.
The US Patent application No. 13/279,949 and 13/279,938 relates to methods for preparing semi-solid delivery extended release formulations of granisetron and methods for treatment of emesis respectively, while patent application No. 12/564,881 relates to compositions for extended delivery of granisetron.
A.P. Pharma president and chief executive officer John Whelan said the new patents are instrumental in bolstering APF530's overall patent life and will extend the intellectual property protection surrounding the product through 2024.
"A.P. Pharma continues to make advancements related to APF530 beyond clinical and regulatory development, and the allowance of these patents provides added strength to the APF530 patent estate and will help support the product's longevity," Whelan added.
